<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow transplantation was performed between IV/82 and X/85 in 64 patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (n = 36), <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>; n = 13), severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n = 12), and <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> stage IV (n = 3) </plain></SENT>
<SENT sid="1" pm="."><plain>Of these patients 57 received allogeneic marrow from HLA-ABCDR identical, MLC-negative sibling donors </plain></SENT>
<SENT sid="2" pm="."><plain>Six transplants were performed with syngenic marrow and one with autologous marrow </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 64 patients 48 survived 40-1,250 days after transplantation, resulting in a survival rate (SR) of 75% and a survival probability (SP) of 71% </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 36 patients suffering from <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (SR = 64%, SP = 51%), patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in first complete remission (n = 11; SR = 81%, SP = 76%), as well as patients with <z:hpo ids='HP_0006721'>acute lymphatic leukemia</z:hpo> (ALL) in 1st to 4th complete remission at the time of transplantation (n = 14; SR = 81%, SP = 76%) show a favorable prognosis </plain></SENT>
<SENT sid="5" pm="."><plain>A poor survival rate was seen for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> when transplanted in second or partial remission (1/5; SR = 20%), as well as for patients suffering from ALL and transplanted during relapse or partial remission (1/6; SR = 16%) </plain></SENT>
<SENT sid="6" pm="."><plain>Of 13 patients suffering from <z:mp ids='MP_0005481'>CML</z:mp> 12 survived the transplantation free of relapse (SR = 93%, SP = 92%), and one patient died from <z:e sem="disease" ids="C0740380" disease_type="Disease or Syndrome" abbrv="">varicella zoster</z:e> <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Of the transplanted patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 12 of 13 are surviving with complete hematologic reconstitution; one patient, however, died on day 10 from a <z:hpo ids='HP_0100806'>sepsis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In our patient group, the SR as well as the SP has been improved through changes in the irradiation protocol concomitant with prophylactic application of anti-CMV hypergammaglobulin, as well as through additional oral medication of Azyklovir </plain></SENT>
<SENT sid="9" pm="."><plain>The 41 patients (BMT No. 7-47) with total body irradiation at one time show an SR of 44% and an SP of 41% </plain></SENT>
<SENT sid="10" pm="."><plain>The following 46 patients (BMT No. 48-93) have reached an SR of 83% and an SP of 74% under the regimen of fractionated total body irradiation, plus prophylaxis with anti-CMV hypergammaglobulin and Azyklovir </plain></SENT>
<SENT sid="11" pm="."><plain>Within this group, no fatal CMV <z:hpo ids='HP_0002090'>pneumonia</z:hpo> was encountered as opposed to six patients lost from CMV <z:hpo ids='HP_0002090'>pneumonia</z:hpo> in the first group </plain></SENT>
</text></document>